Overcoming Therapy Resistance in Ovarian Cancer: From Molecular Mechanisms to Emerging Therapeutic Strategies

Next-Generation Immune Checkpoint Inhibitors in Gastrointestinal Cancers: Mechanisms, Resistance, and Emerging Therapeutic Strategies

Simple Summary Gastrointestinal cancers remain among the most challenging diseases to treat because many tumors contain complex immune system suppression mechanisms that stop the body from destroying cancer cells. While current immunotherapy drugs have transformed care for a small group of patients, most gastrointestinal tumors quickly resist these treatments. This review explains how cancer cells bypass standard therapies and highlights next-generation immune targets currently being developed to overcome this resistance. We examine how combining new immune-boosting drugs with traditional treatments like chemotherapy, radiation, and novel targeted therapies can weaken cancer defenses. Finally, we explore advanced blood tests and digital tissue profiling methods designed to help doctors predict which patients will benefit most from these therapies. By connecting basic tumor biology with innovative clinical strategies, this review aims to help researchers design smarter, more focused and effective treatment combinations for patients with gastrointestinal cancers.

A Comprehensive Review on Breast Cancer

Breast cancer is the most frequently diagnosed malignancy and a leading cause of cancer-related mortality among women worldwide. Its complex molecular heterogeneity, diverse clinical presentation, and therapeutic resistance continue to pose significant challenges to effective disease management. Advances in molecular biology and precision oncology have substantially improved the understanding of breast cancer pathogenesis, enabling earlier diagnosis and the development of personalized treatment strategies. This review summarizes the current knowledge on breast cancer, including its epidemiology, anatomy and biology, etiological factors, molecular pathogenesis, diagnostic approaches, and clinically relevant biomarkers. It further discusses established therapeutic modalities, including surgery, radiotherapy, chemotherapy, endocrine therapy, targeted therapy, and immunotherapy, while highlighting recent advances in antibody-drug conjugates, PARP inhibitors, nanotechnology-based drug delivery systems, artificial intelligence, and precision medicine. These emerging therapeutic approaches have demonstrated considerable potential in improving treatment efficacy, reducing systemic toxicity, and overcoming drug resistance. Despite these advances, tumor heterogeneity, metastatic progression, and treatment resistance remain major barriers to achieving optimal clinical outcomes. Continued research focusing on biomarker discovery, molecular profiling, and innovative therapeutic strategies is essential for advancing personalized breast cancer management and improving patient survival and quality of life.

Emerging and targeted therapeutic strategies in colorectal cancer: molecular mechanisms and clinical perspectives.

Tumor Immunotherapy Resistance: Underlying Mechanisms and Emerging Strategies to Overcome Therapeutic Bottlenecks

This review presents a systematic synthesis of the principal tumor immunotherapy strategies and their corresponding resistance mechanisms. Immunotherapies—including antibody-based therapies, adoptive cell therapies, immune modulators, and novel approaches such as oncolytic viruses and cancer vaccines—work by stimulating or enhancing the patient's immune system to target cancer cells. Nevertheless, they commonly encounter resistance in clinical applications. Resistance mechanisms predominantly stem from tumor-intrinsic factors and tumor microenvironment (TME) factors. To surmount resistance, combination therapies and personalized treatment strategies grounded in TME profiling and biomarkers represent critical future directions.

Emerging Therapeutic Strategies in Small-Cell Lung Cancer: From Adaptive Resistance to Precision Therapy

Background/Objectives: Small-cell lung cancer (SCLC) remains one of the most therapeutically challenging malignancies despite recent advances in chemoimmunotherapy. Although platinum–etoposide combined with programmed death ligand 1 (PD-L1) blockade has modestly improved survival in extensive-stage disease, most patients ultimately develop treatment resistance. This review examines the evolving biological basis of therapeutic resistance and discusses how emerging treatment strategies may be integrated into biologically informed clinical development. Methods: We conducted a narrative review of recent translational studies, clinical trials, regulatory updates, and major oncology meeting presentations addressing emerging therapeutic strategies, biomarkers, and adaptive resistance mechanisms in SCLC. Results: Advances in molecular profiling have established that SCLC comprises dynamically evolving transcriptional states characterized by lineage plasticity, replication-stress dependency, immune suppression, and antigen remodeling. These biological insights have accelerated the development of delta-like ligand 3 (DLL3)-directed immune-redirection strategies, next-generation antibody–drug conjugates, DNA damage response-targeting therapies, and epigenetic approaches. Across these platforms, however, clinical translation remains constrained by antigen heterogeneity, biomarker instability, lineage plasticity, immune dysfunction, and cumulative toxicity. We organize the available evidence across three clinically relevant treatment windows—induction, post-induction residual disease, and relapse—to clarify how therapeutic timing may influence the role and expected clinical performance of each strategy. Conclusions: Future clinical development should prioritize the prospective validation of dynamic biomarkers and treatment strategies tailored to specific disease stages. Such an approach may improve patient selection, guide therapeutic sequencing, and increase the durability of treatment benefit in extensive-stage SCLC.

Regulated cell death in ovarian cancer: molecular mechanisms and therapeutic targets

Ovarian cancer (OC) poses a significant threat to women’s health due to its high malignancy and poor prognosis, with limited efficacy of existing targeted therapies. In recent years, the elucidation of molecular mechanisms underlying regulated cell death (RCD) has substantially broadened our understanding of OC pathogenesis and therapeutic resistance, rendering the modulation of RCD pathways by small-molecule compounds a highly promising therapeutic strategy. This review systematically outlines the mechanistic underpinnings of multiple major RCD subtypes in OC, with a focused summary of advances in innovative small-molecule compounds targeting these pathways; discusses nanodelivery platforms for RCD modulation, predictive biomarkers for patient stratification, and the current landscape of clinical trials targeting RCD in OC; and finally analyzes the opportunities and challenges in clinical translation within this field, aiming to provide novel insights and directions for precision therapy in OC.